Pharmaceutical companies brace for the upcoming Trump administration. Teva Pharmaceuticals (TEVA) CEO Richard Francis joins Seana Smith and Madison Mills on Catalysts to discuss what both the ...

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone.

The treatment also has a 10-minute onset of action that, according to Future, is "demonstrably faster" than the orally-dosed active comparator (tadalafil) used in the study, and also avoids the ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

After hours: 7:59:05 p.m. EST ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.